Skip to content

Vaxcyte, Inc. PCVX Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Moderna logo
ModernaMRNA
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s increase (decrease) in prepaid expense and other assets?
Vaxcyte, Inc. (PCVX) reported increase (decrease) in prepaid expense and other assets of $8.74M in Q1 2026.
How has Vaxcyte, Inc.'s increase (decrease) in prepaid expense and other assets changed year-over-year?
Vaxcyte, Inc.'s increase (decrease) in prepaid expense and other assets increased by 483.3% year-over-year, from $1.5M to $8.74M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.